ArticlePloS one2010
Furin targeted drug delivery for treatment of rhabdomyosarcoma in a mouse model.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 35 citations in OpenAlex.
- Article
- Molecular ZIP codes in targeted drug delivery.Proceedings of the National Academy of Sciences of the United States of America · 2022Review
- The Phospholipid Research Center: Current Research in Phospholipids and Their Use in Drug Delivery.Pharmaceutics · 2020Review
- Tumor penetrating peptides for improved drug delivery.Advanced drug delivery reviews · 2017Review
- The proprotein convertase furin is required to maintain viability of alveolar rhabdomyosarcoma cells.Oncotarget · 2016Article
- The Proprotein Convertase Furin Contributes to Rhabdomyosarcoma Malignancy by Promoting Vascularization, Migration and Invasion.PloS one · 2016Article
- Stimuli-responsive nanomaterials for therapeutic protein delivery.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- A cyclic peptidic serine protease inhibitor: increasing affinity by increasing peptide flexibility.PloS one · 2014Article
- Peptides as targeting elements and tissue penetration devices for nanoparticles.Advanced materials (Deerfield Beach, Fla.) · 2012Review
- Computational prediction of furin cleavage sites by a hybrid method and understanding mechanism underlying diseases.Scientific reports · 2012Article
- On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications.Biomolecular concepts · 2011Article
- FurinDB: A database of 20-residue furin cleavage site motifs, substrates and their associated drugs.International journal of molecular sciences · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Improvement of treatment efficacy and decreased side effects through tumor-targeted drug delivery would be desirable. By panning with a phage-displayed cyclic random peptide library we selected a peptide with strong affinity for RMS in vitro and in vivo. The peptide minimal binding motif Arg-X-(Arg/Lys)(Arg/Lys) identified by alanine-scan, suggested the target receptor to be a proprotein convertase (PC). Expression profiling of all PCs in RMS biopsies and cell lines revealed consistent high expression levels for the membrane-bound furin and PC7. Direct binding of RMS-P3 peptide to furin was demonstrated by affinity chromatography and supported by activity and colocalization studies. Treatment of RMS in mice with doxorubicin coupled to the targeting peptide resulted in a two-fold increase in therapeutic efficacy compared to doxorubicin treatment alone. Our findings indicate surface-furin binding as novel mechanism for therapeutic cell penetration which needs to be further investigated. Furthermore, this work demonstrates that specific targeting of membrane-bound furin in tumors is possible for and suggests that RMS and other tumors might benefit from proprotein convertases targeted drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.